Advertisement
Singapore markets open in 4 hours 31 minutes
  • Straits Times Index

    3,300.04
    -3.15 (-0.10%)
     
  • S&P 500

    5,187.70
    +6.96 (+0.13%)
     
  • Dow

    38,884.26
    +31.99 (+0.08%)
     
  • Nasdaq

    16,332.56
    -16.69 (-0.10%)
     
  • Bitcoin USD

    63,098.36
    -190.94 (-0.30%)
     
  • CMC Crypto 200

    1,309.53
    -55.60 (-4.07%)
     
  • FTSE 100

    8,313.67
    +100.18 (+1.22%)
     
  • Gold

    2,322.50
    -8.70 (-0.37%)
     
  • Crude Oil

    78.57
    +0.09 (+0.11%)
     
  • 10-Yr Bond

    4.4630
    -0.0260 (-0.58%)
     
  • Nikkei

    38,835.10
    +599.03 (+1.57%)
     
  • Hang Seng

    18,479.37
    -98.93 (-0.53%)
     
  • FTSE Bursa Malaysia

    1,605.68
    +8.29 (+0.52%)
     
  • Jakarta Composite Index

    7,123.61
    -7,135.89 (-50.04%)
     
  • PSE Index

    6,618.58
    -33.91 (-0.51%)
     

Syndax Announces Participation at the Stifel 2024 Virtual Targeted Oncology Forum

WALTHAM, Mass., April 10, 2024 /PRNewswire/ -- Syndax Pharmaceuticals (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that Michael A. Metzger, Chief Executive Officer of Syndax, will participate in a fireside chat at the at Stifel 2024 Virtual Targeted Oncology Forum on Wednesday, April 17, 2024, at 11:00 a.m. ET.

A live webcast of the fireside chat can be accessed from the Investor section of the Company's website at www.syndax.com, where a replay of the event will also be available for a limited time.

About Syndax

Syndax Pharmaceuticals is a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies. Highlights of the Company's pipeline include revumenib, a highly selective inhibitor of the menin–KMT2A binding interaction, and axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1 (CSF-1) receptor. For more information, please visit. For more information, please visit www.syndax.com or follow the Company on X (formerly Twitter) and LinkedIn.

ADVERTISEMENT

Syndax Contact

Sharon Klahre
Syndax Pharmaceuticals, Inc.
sklahre@syndax.com
Tel 781.684.9827

SNDX-G

Cision
Cision

View original content:https://www.prnewswire.com/news-releases/syndax-announces-participation-at-the-stifel-2024-virtual-targeted-oncology-forum-302113234.html

SOURCE Syndax Pharmaceuticals, Inc.